S&P 500   5,112.37 (-1.67%)
DOW   37,899.35 (-1.46%)
QQQ   437.54 (-1.76%)
AAPL   174.93 (-0.06%)
MSFT   420.95 (-1.63%)
META   512.37 (-2.06%)
GOOGL   157.53 (-1.18%)
AMZN   185.59 (-1.83%)
TSLA   171.52 (-1.76%)
NVDA   886.80 (-2.14%)
AMD   162.90 (-4.46%)
NIO   4.11 (-7.85%)
BABA   71.90 (-3.94%)
T   16.33 (-0.55%)
F   12.59 (-3.45%)
MU   122.69 (-3.78%)
GE   154.12 (-2.08%)
CGC   7.91 (-2.94%)
DIS   114.27 (-2.46%)
AMC   2.66 (-5.00%)
PFE   25.88 (-1.75%)
PYPL   64.61 (-1.81%)
XOM   121.21 (-0.48%)
S&P 500   5,112.37 (-1.67%)
DOW   37,899.35 (-1.46%)
QQQ   437.54 (-1.76%)
AAPL   174.93 (-0.06%)
MSFT   420.95 (-1.63%)
META   512.37 (-2.06%)
GOOGL   157.53 (-1.18%)
AMZN   185.59 (-1.83%)
TSLA   171.52 (-1.76%)
NVDA   886.80 (-2.14%)
AMD   162.90 (-4.46%)
NIO   4.11 (-7.85%)
BABA   71.90 (-3.94%)
T   16.33 (-0.55%)
F   12.59 (-3.45%)
MU   122.69 (-3.78%)
GE   154.12 (-2.08%)
CGC   7.91 (-2.94%)
DIS   114.27 (-2.46%)
AMC   2.66 (-5.00%)
PFE   25.88 (-1.75%)
PYPL   64.61 (-1.81%)
XOM   121.21 (-0.48%)
S&P 500   5,112.37 (-1.67%)
DOW   37,899.35 (-1.46%)
QQQ   437.54 (-1.76%)
AAPL   174.93 (-0.06%)
MSFT   420.95 (-1.63%)
META   512.37 (-2.06%)
GOOGL   157.53 (-1.18%)
AMZN   185.59 (-1.83%)
TSLA   171.52 (-1.76%)
NVDA   886.80 (-2.14%)
AMD   162.90 (-4.46%)
NIO   4.11 (-7.85%)
BABA   71.90 (-3.94%)
T   16.33 (-0.55%)
F   12.59 (-3.45%)
MU   122.69 (-3.78%)
GE   154.12 (-2.08%)
CGC   7.91 (-2.94%)
DIS   114.27 (-2.46%)
AMC   2.66 (-5.00%)
PFE   25.88 (-1.75%)
PYPL   64.61 (-1.81%)
XOM   121.21 (-0.48%)
S&P 500   5,112.37 (-1.67%)
DOW   37,899.35 (-1.46%)
QQQ   437.54 (-1.76%)
AAPL   174.93 (-0.06%)
MSFT   420.95 (-1.63%)
META   512.37 (-2.06%)
GOOGL   157.53 (-1.18%)
AMZN   185.59 (-1.83%)
TSLA   171.52 (-1.76%)
NVDA   886.80 (-2.14%)
AMD   162.90 (-4.46%)
NIO   4.11 (-7.85%)
BABA   71.90 (-3.94%)
T   16.33 (-0.55%)
F   12.59 (-3.45%)
MU   122.69 (-3.78%)
GE   154.12 (-2.08%)
CGC   7.91 (-2.94%)
DIS   114.27 (-2.46%)
AMC   2.66 (-5.00%)
PFE   25.88 (-1.75%)
PYPL   64.61 (-1.81%)
XOM   121.21 (-0.48%)
NASDAQ:RNAZ

TransCode Therapeutics (RNAZ) Stock Price, News & Analysis

$0.62
-0.02 (-3.72%)
(As of 01:13 PM ET)
Today's Range
$0.61
$0.64
50-Day Range
$0.58
$0.73
52-Week Range
$0.56
$356.00
Volume
87,824 shs
Average Volume
586,948 shs
Market Capitalization
$387,765.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$480.00

TransCode Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
76,260.2% Upside
$480.00 Price Target
Short Interest
Healthy
0.61% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.06mentions of TransCode Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.14) to ($0.67) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.15 out of 5 stars

RNAZ stock logo

About TransCode Therapeutics Stock (NASDAQ:RNAZ)

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

RNAZ Stock Price History

RNAZ Stock News Headlines

Gold Hits New All-Time Highs
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
TransCode Appoints Daniel Vlock As CMO
Gold Hits New All-Time Highs
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
Transcode Therapeutics Inc (RNAZ)
TransCode Collaborates With Debiopharm; Financial Terms Not Disclosed
See More Headlines
Receive RNAZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TransCode Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
4/12/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RNAZ
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$480.00
High Stock Price Target
$480.00
Low Stock Price Target
$480.00
Potential Upside/Downside
+74,988.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-18,550,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.62 per share

Miscellaneous

Free Float
618,000
Market Cap
$402,727.50
Optionable
Not Optionable
Beta
-0.35
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Thomas A. Fitzgerald M.B.A. (Age 72)
    Interim CEO, CFO, President, VP of Administration & Director
    Comp: $358.14k
  • Dr. Philippe P. Calais Ph.D. (Age 65)
    Pharm., Pharm.D., Executive Chairman of the Board
    Comp: $102.5k
  • Dr. Zdravka Medarova Ph.D. (Age 49)
    Co-Founder & Chief Scientific Officer
  • Dr. Anna Moore Ph.D. (Age 62)
    Co-Founder, Scientific Advisor & Member of Scientific Advisory Board
  • Ms. Susan Duggan M.B.A.
    R.N., Senior Vice President of Operations
  • Dr. Daniel R. Vlock M.D. (Age 72)
    Chief Medical Officer

RNAZ Stock Analysis - Frequently Asked Questions

Should I buy or sell TransCode Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TransCode Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RNAZ shares.
View RNAZ analyst ratings
or view top-rated stocks.

What is TransCode Therapeutics' stock price target for 2024?

1 Wall Street research analysts have issued twelve-month price objectives for TransCode Therapeutics' stock. Their RNAZ share price targets range from $480.00 to $480.00. On average, they anticipate the company's share price to reach $480.00 in the next year. This suggests a possible upside of 76,260.2% from the stock's current price.
View analysts price targets for RNAZ
or view top-rated stocks among Wall Street analysts.

How have RNAZ shares performed in 2024?

TransCode Therapeutics' stock was trading at $6.5920 on January 1st, 2024. Since then, RNAZ stock has decreased by 90.5% and is now trading at $0.6286.
View the best growth stocks for 2024 here
.

Are investors shorting TransCode Therapeutics?

TransCode Therapeutics saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 40,000 shares, a drop of 77.1% from the March 15th total of 174,800 shares. Based on an average daily volume of 635,800 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.6% of the shares of the company are short sold.
View TransCode Therapeutics' Short Interest
.

When is TransCode Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our RNAZ earnings forecast
.

How were TransCode Therapeutics' earnings last quarter?

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) posted its quarterly earnings data on Tuesday, November, 14th. The company reported ($67.20) earnings per share for the quarter, missing analysts' consensus estimates of ($60.00) by $7.20.

When did TransCode Therapeutics' stock split?

TransCode Therapeutics's stock reverse split before market open on Tuesday, January 16th 2024. The 1-40 reverse split was announced on Tuesday, January 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did TransCode Therapeutics IPO?

TransCode Therapeutics (RNAZ) raised $25 million in an initial public offering (IPO) on Friday, July 9th 2021. The company issued 6,250,000 shares at a price of $4.00 per share.

How do I buy shares of TransCode Therapeutics?

Shares of RNAZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RNAZ) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners